180 Life Sciences Corp. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2019 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
180 Life Sciences Corp. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2019 to Q3 2023.
  • 180 Life Sciences Corp. Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $2.3M.
  • 180 Life Sciences Corp. annual Deferred Income Tax Expense (Benefit) for 2023 was -$2.35M, a 149% decline from 2022.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $2.3M Sep 1, 2023 Sep 30, 2023 10-K 2024-03-25
Q1 2022 -$22.3K -$16.9K -313% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q1 2021 -$5.4K -$10.4K -208% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q2 2020 $1.5K -$68.5K -97.9% Apr 1, 2020 Jun 30, 2020 10-Q/A 2021-02-05
Q1 2020 $5K -$91K -94.8% Jan 1, 2020 Mar 31, 2020 10-Q 2020-05-22
Q2 2019 $70K Apr 1, 2019 Jun 30, 2019 10-Q/A 2021-02-05
Q1 2019 $96K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.